 Intellectual PropertyEyeGate's technology platform benefits from an exclusive worldwide patent position covering all the technical features of the EyeGate® II Delivery System and the kind of drugs that it can deliver. Our principle patent is licensed from the University of Miami. EyeGate Pharma has further strengthened its intellectual property position with extensive worldwide fillings covering improvements to the system. The company believes that its intellectual property position is a major asset which gives it both freedom to operate and a dominant position within ocular iontophoresis which, if challenged, will defend vigorously. |
|
 |
